Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors

INTRODUCTION: Combination therapeutic mode is likely to be the key to enhance the efficacy of immunotherapy in a wider range of cancer patients. Herein, we conducted an open-label, single-arm, multicenter, phase II clinical trial that enrolled patients with advanced solid tumors who had progressed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jie, Yan, Jing, Du, Juan, Li, Xiaoqin, Wei, Jia, Liu, Qin, Yong, Hongmei, Wang, Xiaolu, Chang, Xiaofeng, Ding, Zhou, Sun, Wu, Liu, Chenxi, Zhu, Sihui, Guo, Jingyi, Li, Huajun, Liu, Ying, Zhang, Wulou, Liu, Zonghang, Li, Rutian, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086408/
https://www.ncbi.nlm.nih.gov/pubmed/37056765
http://dx.doi.org/10.3389/fimmu.2023.1133689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086408/
https://www.ncbi.nlm.nih.gov/pubmed/37056765
http://dx.doi.org/10.3389/fimmu.2023.1133689

Ejemplares similares